The estimated Net Worth of Andreas Busch is at least $4.02 Milion dollars as of 9 November 2020. Andreas Busch owns over 125,000 units of Cyclerion Therapeutics stock worth over $765,386 and over the last 6 years he sold CYCN stock worth over $0. In addition, he makes $3,251,110 as Chief Innovation Officer i Head of the Innovation Center at Cyclerion Therapeutics.
Sign up
Andreas Busch CYCN stock SEC Form 4 insiders trading
Andreas has made over 2 trades of the Cyclerion Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 125,000 units of CYCN stock worth $316,250 on 9 November 2020.
The largest trade he's ever made was buying 125,000 units of Cyclerion Therapeutics stock on 9 November 2020 worth over $316,250. On average, Andreas trades about 35,714 units every 51 days since 2019. As of 9 November 2020 he still owns at least 254,704 units of Cyclerion Therapeutics stock.
You can see the complete history of Andreas Busch stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Andreas Busch biography
Prof. Dr. Andreas Busch serves as Chief Innovation Officer, Head of the Innovation Center of the Company. He has served as our Chief Innovation Officer, Head of the Innovation Center since joining Cyclerion on April 29, 2019. Prior to joining Cyclerion, Dr. Busch served as the Head of Research and Development and Chief Scientific Officer at Shire plc, a position he held since January 2018. From May 2005 to December 2017, Dr. Busch held various positions at Bayer AG, including Head of Drug Discovery for Bayer Pharma and Bayer Animal Health from January 2016 to December 2017 and Executive Vice President, Global Head Drug Discovery for Bayer HealthCare and Bayer Pharma from December 2006 to December 2015. Additionally, Dr. Busch served as a member of the Executive Committee of Bayer HealthCare from February 2007 to December 2015. Prior to that, Dr. Busch was Global Head of Cardiovascular Research at Hoechst and Sanofi-Aventis. Dr. Busch holds a Ph.D. in pharmacology and is extra-ordinary Professor at the Johann Wolfgang Goethe-University Frankfurt.
What is the salary of Andreas Busch?
As the Chief Innovation Officer i Head of the Innovation Center of Cyclerion Therapeutics, the total compensation of Andreas Busch at Cyclerion Therapeutics is $3,251,110. There are no executives at Cyclerion Therapeutics getting paid more.
How old is Andreas Busch?
Andreas Busch is 56, he's been the Chief Innovation Officer i Head of the Innovation Center of Cyclerion Therapeutics since 2019. There are 12 older and 2 younger executives at Cyclerion Therapeutics. The oldest executive at Cyclerion Therapeutics, Inc. is George Conrades, 81, who is the Independent Director.
What's Andreas Busch's mailing address?
Andreas's mailing address filed with the SEC is C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA, 02142.
Insiders trading at Cyclerion Therapeutics
Over the last 6 years, insiders at Cyclerion Therapeutics have traded over $240,273 worth of Cyclerion Therapeutics stock and bought 4,653,203 units worth $33,009,775 . The most active insiders traders include Peter M Hecht, Mark G Currie oraz Terrance Mcguire. On average, Cyclerion Therapeutics executives and independent directors trade stock every 84 days with the average trade being worth of $749,841. The most recent stock trade was executed by Terrance Mcguire on 9 August 2023, trading 8 units of CYCN stock currently worth $27.
What does Cyclerion Therapeutics do?
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
What does Cyclerion Therapeutics's logo look like?
Complete history of Andreas Busch stock trades at Cyclerion Therapeutics
Cyclerion Therapeutics executives and stock owners
Cyclerion Therapeutics executives and other stock owners filed with the SEC include:
-
Andreas Busch,
Chief Innovation Officer, Head of the Innovation Center -
Dr. Andreas Busch Ph.D.,
Chief Scientific Officer -
Mark Currie,
President, Chief Scientific Officer -
Marsha Fanucci,
Independent Chairman of the Board -
Terrance McGuire,
Independent Director -
Amy Schulman,
Independent Director -
George Conrades,
Independent Director -
Stephanie Lovell,
Independent Director -
Ole Isacson,
Independent Director -
Kevin Churchwell,
Independent Director -
Michael Mendelsohn,
Independent Director -
Peter Hecht,
Chief Executive Officer, Director -
Dr. Peter M. Hecht Ph.D.,
CEO, Interim CFO, Principal Accounting Officer & Director -
William Huyett,
Chief Financial Officer -
Jennifer Chickering,
Sr. Director of Clinical Strategy -
Christopher Winrow,
Sr. Director of Clinical Devel. & Neuroscience Program Lead -
Jessica Rennekamp,
Associate Director of Corp. Communications -
Dr. Todd Milne Ph.D.,
VP of Corp. Devel. -
Cheryl Gault,
Chief Operating Officer -
Anjeza Gjino,
CFO & Corp. Sec. (Maternity Leave of Absence) -
Regina Margaret Graul,
See Remarks -
Path Capital Lp Greenspan D...,
-
Christopher I Wright,
Chief Medical Officer -
Anjeza Gjino,
Chief Financial Officer -
Errol B Desouza,
-
Pharmaceuticals Inc Ironwood,
10% owner -
Cheryl Gault,
Chief Operating Officer -
Steven Hyman,